Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:09 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 2,209 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Melanoma Neoplasms Clear all
Recruiting No phase listed Observational

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

NCT06887348
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
Observational study with no interventions
Other
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional Results available

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

NCT01726738
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
Interventions
BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 1 Interventional

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

NCT00003897
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gp100 antigen, sargramostim
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Nov 3, 2026, 11:09 AM EST
Withdrawn Phase 2 Interventional

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

NCT01363206
View directory record Official record
Conditions
Malignant Melanoma, Metastatic
Interventions
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Ipilimumab
Biological
Lead sponsor
Lynn E. Spitler, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

NCT00001685
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 11:09 AM EST
Not listed Phase 1 Interventional

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

NCT03743298
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
AV-MEL-1
Drug
Lead sponsor
Aivita Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Irvine, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Nov 3, 2026, 11:09 AM EST
Terminated Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

NCT02723006
View directory record Official record
Conditions
Melanoma
Interventions
TAK-580, TAK-202, vedolizumab, nivolumab, ipilimumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Nov 3, 2026, 11:09 AM EST
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 3, 2026, 11:09 AM EST
Terminated Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01468818
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional Results available

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Other Solid Tumors
Interventions
TALIMOGENE LAHERPAREPVEC (TVEC), Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Middletown, New Jersey • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional Results available

Radiation and Combination Immunotherapy for Melanoma

NCT03850691
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Aldesleukin: All Patients, Nivolumab: Cohort 1 (Cutaneous), Nivolumab: Cohort 2 (Ocular), Ipilimumab: Cohort 2 (Ocular)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Burnsville, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional Results available

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

NCT01118091
View directory record Official record
Conditions
Skin Cancer, Melanoma, Metastatic Melanoma
Interventions
Aldesleukin, CD8 enriched Young TIL
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 3 Interventional Results available

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

NCT01106040
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Lymphoseek
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Nov 3, 2026, 11:09 AM EST
Withdrawn Not applicable Interventional

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

NCT02309632
View directory record Official record
Conditions
Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
Interventions
Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Nov 3, 2026, 11:09 AM EST
Completed No phase listed Observational

Melanoma Detection by Oblique-Incidence Optical Spectroscopy

NCT00526032
View directory record Official record
Conditions
Skin Cancer
Interventions
OIR Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Nov 3, 2026, 11:09 AM EST
Not listed Phase 2 Interventional

A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma

NCT00925314
View directory record Official record
Conditions
Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
CB-10-01 (Transgenic Lymphocyte Immunization)
Biological
Lead sponsor
Cosmo Bioscience
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Nov 3, 2026, 11:09 AM EST
Completed No phase listed Observational

Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

NCT00588198
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 3, 2026, 11:09 AM EST
Recruiting Phase 2 Interventional

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT04114136
View directory record Official record
Conditions
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions
Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
Drug
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional Results available

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

NCT01266967
View directory record Official record
Conditions
Melanoma and Brain Metastases
Interventions
GSK2118436
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Nov 3, 2026, 11:09 AM EST
Completed Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01993719
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Nov 3, 2026, 11:09 AM EST
Active, not recruiting Not applicable Interventional

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

NCT05053230
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Tumor, Thoracic Tumor, Thoracic Cancer, Gynecologic Cancer, Gynecologic Tumor, Melanoma, Ovarian Cancer
Interventions
IM@Home, Enhanced usual care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 11:09 AM EST
Terminated Phase 2 Interventional Results available

High Dose IL-2 in Combination With Anti-PD-1

NCT03991130
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Metastatic
Interventions
IL-2 and Nivolumab
Drug
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 3, 2026, 11:09 AM EST